A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma
Glenn J. Hanna(Dana-Farber Cancer Institute), Robert I. Haddad(Georgetown University), Lori J. Wirth(Massachusetts General Hospital), Jeffrey K. Mito(Brigham and Women's Hospital), Jennifer M. Cutler(Dana-Farber Cancer Institute), Jens G. Lohr(Dana-Farber Cancer Institute), Jong Chul Park(Harvard University), Michelle Flynn(Dana-Farber Cancer Institute), Nicole Spardy Burr, Leonard I. Zon(Harvard University Press), John R. Clark(Harvard University), Tushara Vijaykumar(Dana-Farber Cancer Institute), Jochen H. Lorch(Northwestern University), Anne O’Neill(International Breast Cancer Study Group), Jeffrey L. Kaufman(Neuroendocrine Tumor Research Foundation)
Cited by 51
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter
|Nature|2000|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
In vivo drug discovery in the zebrafish
|Nature Reviews Drug Discovery|2005|1.4k